全文获取类型
收费全文 | 177篇 |
免费 | 19篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 3篇 |
基础医学 | 31篇 |
口腔科学 | 4篇 |
临床医学 | 24篇 |
内科学 | 68篇 |
皮肤病学 | 1篇 |
神经病学 | 5篇 |
特种医学 | 7篇 |
外科学 | 12篇 |
综合类 | 8篇 |
预防医学 | 5篇 |
眼科学 | 1篇 |
药学 | 3篇 |
中国医学 | 4篇 |
肿瘤学 | 28篇 |
出版年
2023年 | 1篇 |
2022年 | 6篇 |
2021年 | 6篇 |
2020年 | 4篇 |
2019年 | 6篇 |
2018年 | 13篇 |
2017年 | 9篇 |
2016年 | 4篇 |
2015年 | 8篇 |
2014年 | 11篇 |
2013年 | 8篇 |
2012年 | 10篇 |
2011年 | 14篇 |
2010年 | 15篇 |
2009年 | 6篇 |
2008年 | 11篇 |
2007年 | 3篇 |
2006年 | 8篇 |
2005年 | 6篇 |
2004年 | 7篇 |
2003年 | 2篇 |
2002年 | 5篇 |
2001年 | 2篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1990年 | 1篇 |
1987年 | 1篇 |
1984年 | 1篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 4篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1973年 | 4篇 |
1972年 | 3篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1968年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有205条查询结果,搜索用时 15 毫秒
201.
Natalie Callander Stephanie Markovina Jens Eickhoff Paul Hutson Toby Campbell Peiman Hematti Ronald Go Robert Hegeman Walter Longo Eliot Williams Fotis Asimakopoulos Shigeki Miyamoto 《Cancer chemotherapy and pharmacology》2014,74(4):875-882
Purpose
Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN). We incorporated acetyl-l-carnitine (ALCAR) to prevent PN and allow for adequate dosing. We also investigated the correlation between B-inducible NF-κB activation and response to therapy.Methods
Nineteen patients with relapsed/refractory MM received up to 8 cycles of intravenous bortezomib, doxorubicin and oral low-dose dexamethasone (BDD) to evaluate response and toxicity. Thirteen additional patients received prophylactic ALCAR (BDD-A). Patients receiving BDD-A were evaluated by FACT-GOG-TX, FACIT-Fatigue, Neuropathic Pain index (NPI) and Grooved Pegboard (GP) testing. Primary MM cells from 11 patients were tested for B-inducible NF-κB activation.Results
Seventy-six percent of subjects were refractory to previous treatment, 39 % refractory to bortezomib. Median cycles received were 5. CR + PR for the entire group were 53 % and did not differ between groups. Incidence of ≥3 PN was 32 % in the BDD group versus 15 % in the BDD-A group (p = ns). Patient-reported fatigue and PN measured by FACT-GOG-TX increased throughout the treatment period in the BDD-A group, although time to complete GP testing declined. In a sub-study examining constitutive bortezomib-inducible NF-κB activity in primary subject-specific MM cells, the presence of NF-κB activation correlated with lower likelihood of response.Conclusions
Addition of ALCAR to BDD did not alter the incidence or severity of PN in relapsed MM patients receiving a B-based regimen. Bortezomib-inducible NF-κB activation in patient-derived primary MM cells may be associated with poorer response. 相似文献202.
203.
204.
205.